Carlton Hofferkamp & Jenks Wealth Management LLC Sells 71 Shares of Amgen Inc. (NASDAQ:AMGN)

Carlton Hofferkamp & Jenks Wealth Management LLC lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,789 shares of the medical research company’s stock after selling 71 shares during the period. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Amgen were worth $1,518,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Edmond DE Rothschild Holding S.A. grew its holdings in shares of Amgen by 63.5% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 2,230 shares of the medical research company’s stock worth $634,000 after purchasing an additional 866 shares during the last quarter. Angeles Wealth Management LLC purchased a new position in Amgen in the first quarter worth about $210,000. Delta Investment Management LLC boosted its holdings in shares of Amgen by 8.6% in the first quarter. Delta Investment Management LLC now owns 1,842 shares of the medical research company’s stock worth $524,000 after buying an additional 146 shares during the last quarter. Beacon Investment Advisory Services Inc. grew its position in shares of Amgen by 41.3% during the 1st quarter. Beacon Investment Advisory Services Inc. now owns 41,950 shares of the medical research company’s stock valued at $11,927,000 after acquiring an additional 12,268 shares during the period. Finally, Kingsview Wealth Management LLC grew its holdings in Amgen by 10.1% during the first quarter. Kingsview Wealth Management LLC now owns 63,452 shares of the medical research company’s stock valued at $18,041,000 after purchasing an additional 5,819 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on AMGN shares. StockNews.com raised Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 price objective (down previously from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Robert W. Baird reiterated an “underperform” rating and issued a $215.00 target price on shares of Amgen in a report on Wednesday, September 25th. Jefferies Financial Group restated a “buy” rating and set a $380.00 target price on shares of Amgen in a research report on Tuesday. Finally, TD Cowen boosted their price objective on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Amgen has an average rating of “Moderate Buy” and a consensus price target of $333.50.

Amgen Stock Performance

NASDAQ AMGN opened at $298.84 on Wednesday. The business has a 50 day moving average price of $322.74 and a 200 day moving average price of $318.27. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The company has a market capitalization of $160.64 billion, a P/E ratio of 38.26, a PEG ratio of 2.87 and a beta of 0.60. Amgen Inc. has a 1-year low of $260.52 and a 1-year high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter in the previous year, the company posted $4.96 EPS. The business’s revenue was up 23.2% on a year-over-year basis. Sell-side analysts expect that Amgen Inc. will post 19.51 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.01%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s payout ratio is currently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.